U.S. Patent and Trademark Office rules in favour of Mylan
Natco Pharma announced that U.S. Patent and Trademark Office has ruled in favour of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of two related Copaxone 40 mg/mL patents to be un-patentable.Natco's marketing partner, Mylan believes its is one of the first companies to have filled a substantially complete abbreviated new drug application containing Paragraph IV certification for a three times per week Glatiramer Acetate Injection 40 mg/ ML and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app